Explore › Intervention › Abnormal female sex hormone
Intervention

Abnormal female sex hormone

Also known as: Abnormal female sex hormone Abnormal female sex hormone (finding) Female sex and younger age (2-12 years) as demographic predictors of anxiety disorder comorbidity among youth with substance use disorders Female sex hormones abnormal Female sex hormones abnormal (finding) Female sex hormones abnormal (situation) AD
3 findings 1 paper 4 related entities View in graph →

Related entities

conditions
Psychoactive substance use disorder1
outcomes
Leukocyte Nuclear Appendages, Hereditary Prevalence of1
populations
Children1
studys
PMC31962791

Findings (27)

None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →
None
decline

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema
PMC3196279
Finding details → · Paper → · Graph →

Papers (1)